28 februari 2022: Bron: Harvard en Mediwiet
Op de website van mediwiet een lang artikel over de tussenresultaten van medicinaal cannabis gebruik uit een kleine observatiestudie die wordt uitgevoerd aan de Harvard universiteit. Maar hoewel er maar totaal 37 patiënten met chronische pijn worden gevolgd in deze observatie studie zijn de tussenresultaten toch wel opmerkelijk positief voor de medicinale cannabis, maar wel bij maar een paar patiënten.
Deze tussentijdse analyses omvatten 37 patiënten met chronische pijn die werden geëvalueerd voorafgaand aan de start van de Medicinale Cannabis behandeling en na 3 en 6 maanden Medicinaal Cannabis gebruik; pijn, klinische toestand, slaap, kwaliteit van leven en conventioneel medicatiegebruik werden beoordeeld.
Daarnaast werden ook bij 9 controlepatiënten die geen medicinale cannabis gebruikten beoordeeld volgens dezelfde meetpunten.
Ten opzichte van de baselinemetingen vertoonden Medicinale cannabis patiënten na 3 en 6 maanden behandeling verbeteringen in pijn die gepaard gingen met verbeterde slaap, stemming, angst en kwaliteit van leven, en stabiel conventioneel medicatiegebruik. Verminderde pijn werd geassocieerd met verbeteringen in aspecten van stemming en angst. De resultaten suggereren over het algemeen dat verhoogde THC-blootstelling verband hield met pijngerelateerde verbetering, terwijl verhoogde CBD-blootstelling verband hield met een verbeterde stemming. In de controlegroep werden geen verbeteringen gezien.
De studie is in april 2021 gepubliceerd, abstract staat onderaan artikel: No pain, all gain? Interim analyses from a longitudinal, observational study examining the impact of medical cannabis treatment on chronic pain and related symptoms
Een vergelijkbare studie of misschein wel dezelfde is deze, zie ook abstract verderop in dit artikel:
Health Outcomes among Adults Initiating Medical Cannabis for Chronic Pain: A 3-month Prospective Study Incorporating Ecological Momentary Assessment (EMA)
Ik geef hier maar het artikel op de website van mediwiet omdat zij goed kunnen uitleggen hoe medicinale cannabis werkt en ook nog andere studies citeren. Voor alle duidelijkheid wij hebben geen enkel contact met mediwiet en wat zij schrijven en aanbieden is volledig voor hun verantwoording. Zie ook onze disclaimer
Harvard studie: chronische pijnpatiënten zien langdurig succes met medicinale cannabis
Nieuw onderzoek van de Harvard Medical School en het Mclean Hospital in Boston wijst uit wat miljoenen pijnpatiënten over de hele wereld uit eigen ondervinding weten: patiënten met chronische pijn ervaren een aanhoudende verbetering van hun symptomen door het gebruik van medicinale cannabis.
Pijnpatiënten langdurig gemonitord
De studie ‘No pain, all gain? Interim analyses from a longitudinal, observational study examining the impact of medical cannabis treatment on chronic pain and related symptoms’ zal worden gepubliceerd in het tijdschrift Experimental and Clinical Psychopharmacology. Een samenvatting verscheen begin april online. 37 patiënten met chronische pijn die medicinale cannabis gebruiken worden langdurig gevolgd voor het onderzoek. Het gaat vooral om mensen met musculoskeletale pijn of neuropathie.
De onderzoekers kijken onder meer naar pijn, slaap, kwaliteit van leven en gebruik van reguliere medicijnen vóór het begin van de behandeling met medicinale cannabis en daarna met een vaste regelmaat van drie maanden. Een controlegroep met pijnpatiënten die reguliere medicijnen kregen en géén medicinale cannabis werd geanalyseerd bij het begin van de onderzoeksperiode – de baseline – en na drie maanden.>>>>>>>>>lees verder artikel op website van mediwiet.
[Bronnen:
Research Shows Chronic Pain Patients See Sustained Improvement With Cannabis Use, HighTimes.com, 9 april 2021
Study: Cannabis Associated with Sustained Improvements in Chronic Pain Patients, NORML.org, 8 april 2021
Analysis: Medical Cannabis Most Commonly Recommended for Treating Chronic Pain Conditions, NORML.org, 11 februari 2021]
Health Outcomes among Adults Initiating Medical Cannabis for Chronic Pain: A 3-month Prospective Study Incorporating Ecological Momentary Assessment (EMA)
Abstract
In response to the need of more rigorous data on medical cannabis and chronic pain, we conducted a 3-month prospective study incorporating ecological momentary assessment (EMA) to examine the effects of medical cannabis on pain, anxiety/depression, sleep, and quality of life. Data were collected from 46 adults (Mean age=55.7±11.9, 52.2% male) newly initiating medical cannabis treatment for chronic pain. Participants completed a baseline survey, EMA for approximately 1 week pre- and up to 3 weeks post- medical cannabis treatment, and a 3-month follow-up survey. The self-reported EMA data (2535 random and 705 daily assessments) indicated significant reductions in momentary pain intensity (b = −16.5, p < .001, 16.5 points reduction on 0–100 visual analog) and anxiety (b = −0.89, p < .05), and significant increase in daily sleep duration (b = 0.34, p < .01) and sleep quality (b = 0.32, p <.001) after participants initiated medical cannabis for a few weeks. At 3 months, self-reported survey data showed significantly lower levels of worst pain (t = −2.38, p < .05), pain interference (t = −3.82, p < .05), and depression (t = −3.43, p < .01), as well as increased sleep duration (t = 3.95, p < .001), sleep quality (t = −3.04, p < .01), and quality of life (t = 4.48, p
Observational Study
No pain, all gain? Interim analyses from a longitudinal, observational study examining the impact of medical cannabis treatment on chronic pain and related symptoms
- PMID: 33764103
- DOI: 10.1037/pha0000435
Abstract
Previous studies have demonstrated improvements in pain following short-term medical cannabis (MC) use, suggesting long-term MC treatment may alleviate symptoms associated with chronic pain. The goal of this observational and longitudinal study was to examine patients using MC to treat chronic pain pre versus post MC treatment. These interim analyses included 37 patients with chronic pain evaluated prior to initiation of MC treatment and following 3 and 6 months of MC use; pain, clinical state, sleep, quality of life, and conventional medication use were assessed. Correlation analyses examined the relationship between changes in pain and other clinical measures, assessed the impact of cannabinoid exposure on pain and clinical ratings, and assessed whether baseline cannabis expectancies influenced outcome variables. Additionally, a pilot group of treatment-as-usual patients (n = 9) who did not use MC were examined at baseline and 3 months later. Relative to baseline, following 3 and 6 months of treatment, MC patients exhibited improvements in pain which were accompanied by improved sleep, mood, anxiety, and quality of life, and stable conventional medication use. Reduced pain was associated with improvements in aspects of mood and anxiety. The results generally suggest increased THC exposure was related to pain-related improvement, while increased CBD exposure was related to improved mood. Cannabis expectancies were not related to observed improvements. Pilot analyses revealed that treatment-as-usual patients do not demonstrate the same pattern of improvement. Findings highlight the potential efficacy of MC treatment for pain and underscore the unique impact of individual cannabinoids on specific aspects of pain and comorbid symptoms. (PsycInfo Database Record (c) 2021 APA, all rights reserved).
Similar articles
-
An Observational, Longitudinal Study of Cognition in Medical Cannabis Patients over the Course of 12 Months of Treatment: Preliminary Results.Sagar KA, Dahlgren MK, Lambros AM, Smith RT, El-Abboud C, Gruber SA.J Int Neuropsychol Soc. 2021 Jul;27(6):648-660. doi: 10.1017/S1355617721000114.PMID: 34261553
-
Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis.Black N, Stockings E, Campbell G, Tran LT, Zagic D, Hall WD, Farrell M, Degenhardt L.Lancet Psychiatry. 2019 Dec;6(12):995-1010. doi: 10.1016/S2215-0366(19)30401-8. Epub 2019 Oct 28.PMID: 31672337 Free PMC article.
-
Cannabis and Cannabinoids for Chronic Pain.Romero-Sandoval EA, Kolano AL, Alvarado-Vázquez PA.Curr Rheumatol Rep. 2017 Oct 5;19(11):67. doi: 10.1007/s11926-017-0693-1.PMID: 28983880 Review.
-
High-Frequency Medical Cannabis Use Is Associated With Worse Pain Among Individuals With Chronic Pain.Boehnke KF, Scott JR, Litinas E, Sisley S, Williams DA, Clauw DJ.J Pain. 2020 May-Jun;21(5-6):570-581. doi: 10.1016/j.jpain.2019.09.006. Epub 2019 Sep 24.PMID: 31560957 Free PMC article.
-
Cannabis-based medicines for chronic neuropathic pain in adults.Mücke M, Phillips T, Radbruch L, Petzke F, Häuser W.Cochrane Database Syst Rev. 2018 Mar 7;3(3):CD012182. doi: 10.1002/14651858.CD012182.pub2.PMID: 29513392 Free PMC article. Review.
Cited by 1 article
-
Health Outcomes among Adults Initiating Medical Cannabis for Chronic Pain: A 3-month Prospective Study Incorporating Ecological Momentary Assessment (EMA).Wang Y, Jean Jacques J, Li Z, Sibille KT, Cook RL.Cannabis. 2021 Oct;4(2):69-83. doi: 10.26828/cannabis/2021.02.006.PMID: 34671723 Free PMC article.
REFERENCES
- Amtmann D, Cook KF, Jensen MP, Chen WH, Choi S, Revicki D, Cella D, Rothrock N, Keefe F, Callahan L, & Lai JS (2010). Development of a PROMIS item bank to measure pain interference. Pain, 150(1), 173–182. [PMC free article] [PubMed] [Google Scholar]
- Bates D, Mächler M, Bolker B, & Walker S (2015). Fitting linear mixed-effects models using lme4. Journal of Statistical Software, 67(1), 1–48. [Google Scholar]
- Boehnke KF, Scott JR, Litinas E, Sisley S, Williams DA, & Clauw DJ (2019). Pills to pot: Observational analyses of cannabis substitution among medical cannabis users with chronic pain. The Journal of Pain, 20 (7), 830–841. [PubMed] [Google Scholar]
- Bolger N, & Laurenceau J-P (2013). Intensive Longitudinal Methods: An Introduction to Diary and Experience Sampling Research. Guilford Publications. [Google Scholar]
- Bomyea J, Lang A, Craske MG, Chavira DA, Sherbourne CD, Rose RD, Golinelli D, Campbell-Sills L, Welch SS, Sullivan G, Bystritsky A, Roy-Byrne P, & Stein MB (2015). Course of symptom change during anxiety treatment: Reductions in anxiety and depression in patients completing the Coordinated Anxiety Learning and Management program. Psychiatry Research, 229(1–2), 133–142. [PMC free article] [PubMed] [Google Scholar]
- Brown JD, Costales B, van Boemmel-Wegmann S, Goodin AJ, Segal R, & Winterstein AG (2020). Characteristics of older adults who were early adopters of medical cannabis in the Florida Medical Marijuana Use Registry. Journal of Clinical Medicine, 9(4). [PMC free article] [PubMed] [Google Scholar]
- Buysse DJ, Reynolds CF, Monk TH, Berman SR, & Kupfer DJ (1989). The Pittsburgh Sleep Quality Index: A new instrument for psychiatric practice and research. Psychiatry Research, 28(2), 193–213. [PubMed] [Google Scholar]
- Cain AE, Depp CA, & Jeste DV (2009). Ecological momentary assessment in aging research: a critical review. Journal of Psychiatric Research, 43(11), 987–996. [PMC free article] [PubMed] [Google Scholar]
- Cleeland CS, & Ryan KM (1994). Pain assessment: global use of the Brief Pain Inventory. Annals of the Academy of Medicine Singapore(23), 2. [PubMed] [Google Scholar]
- Cleeland CS (2009). The Brief Pain Inventory User Guide. Retrieved July 7, 2021, from https://www.mdanderson.org/education-and-research/departments-programs-and-labs/departments-and-divisions/symptom-research/symptom-assessment-tools/BPI_UserGuide.pdf
- Cleveland WS (1979). Robust locally weighted regression and smoothing scatterplots. Journal of the American Statistical Association, 74(368), 829–836. [Google Scholar]
- Cooke AC, Knight KR, & Miaskowski C (2019). Patients’ and clinicians’ perspectives of co-use of cannabis and opioids for chronic non-cancer pain management in primary care. The International Journal on Drug Policy, 63, 23–28. [PMC free article] [PubMed] [Google Scholar]
- Dahlhamer J, Lucas J, Zelaya C, Nahin R, Mackey S, DeBar L, Kerns R, Von Korff M, Porter L, & Helmick C (2018). Prevalence of chronic pain and high-impact chronic pain among adults - United States, 2016. MMWR.Morbidity and Mortality Weekly Report, 67(36), 1001–1006. [PMC free article] [PubMed] [Google Scholar]
- Derogatis LR, & Melisaratos N (1983). The Brief Symptom Inventory: an introductory report. Psychological Medicine, 13(3), 595–605. [PubMed] [Google Scholar]
- Deshpande A, Mailis-Gagnon A, Zoheiry N, & Lakha SF (2015). Efficacy and adverse effects of medical marijuana for chronic noncancer pain: Systematic review of randomized controlled trials. Canadian Family Physician Medecin de Famille Canadien, 61(8), E372–E381. [PMC free article] [PubMed] [Google Scholar]
- Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP, Kerns RD, Stucki G, Allen RR, Bellamy N, Carr DB, Chandler J, Cowan P, Dionne R, Galer BS, Hertz S, Jadad AR, Kramer LD, Manning DC, Martin S, McCormick CG, McDermott MP, McGrath P, Quessy S, Rappaport BA, Robbins W, Robinson JP, Rothman M, Royal MA, Simon L, Stauffer JW, Stein W, Tollett J, Wernicke J, Witter J, & IMMPACT. (2005). Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain, 113(1–2), 9–19. [PubMed] [Google Scholar]
- Dyer O (2019). Access to medical marijuana does not reduce opioid overdoses in US, study finds. BMJ (Clinical research ed.), 365, l4188. [PubMed] [Google Scholar]
- Emery NN, Carpenter RW, Treloar Padovano H, & Miranda R (2020). Why don’t they stop? Understanding unplanned marijuana use among adolescents and young adults. Psychology of Addictive Behaviors: Journal of the Society of Psychologists in Addictive Behaviors, 34(5), 579–589. [PMC free article] [PubMed] [Google Scholar]
- Fisher E, Moore RA, Fogarty AE, Finn DP, Finnerup NB, Gilron I, Haroutounian S, Krane E, Rice ASC, Rowbotham M, Wallace M, & Eccleston C (2021). Cannabinoids, cannabis, and cannabis-based medicine for pain management: a systematic review of randomised controlled trials. Pain, 162(Suppl 1), S45–S66. [PubMed] [Google Scholar]
- Florida Department of Health. (2020). Office of Medical Marijuana Use (OMMU) weekly updates. https://knowthefactsmmj.com/about/weekly-updates/
- Gruber SA, Smith RT, Dahlgren MK, Lambros AM, & Sagar KA (2021). No pain, all gain? Interim analyses from a longitudinal, observational study examining the impact of medical cannabis treatment on chronic pain and related symptoms. Experimental and Clinical Psychopharmacology, 29(2), 147–156. [PubMed] [Google Scholar]
- IASP Presidential Task Force on Cannabis and Cannabinoid Analgesia (2021). International Association for the Study of Pain Presidential Task Force on cannabis and cannabinoid analgesia position statement. Pain, 162(Suppl 1), S1–S2. [PubMed] [Google Scholar]
- Kaptchuk TJ (2002). The placebo effect in alternative medicine: can the performance of a healing ritual have clinical significance? Annals of Internal Medicine, 136(11), 817–825. [PubMed] [Google Scholar]
- Kroenke K, Spitzer RL, & Williams JB (2001). The PHQ-9: validity of a brief depression severity measure. Journal of General Internal Medicine, 16(9), 606–613. [PMC free article] [PubMed] [Google Scholar]
- Kroenke K, Strine TW, Spitzer RL, Williams JB, Berry JT, & Mokdad AH (2009). The PHQ-8 as a measure of current depression in the general population. Journal of Affective Disorders, 114(1–3), 163–173. [PubMed] [Google Scholar]
- Lev-Ran S, Roerecke M, Le Foll B, George T, McKenzie K, & Rehm J (2013). The Association between cannabis use and depression: A systematic review and meta-analysis of longitudinal studies. European Psychiatry, 28(S1), 1–1. [Google Scholar]
- Löwe B, Decker O, Müller S, Brähler E, Schellberg D, Herzog W, & Herzberg PY (2008). Validation and standardization of the Generalized Anxiety Disorder Screener (GAD-7) in the general population. Medical Care, 46(3), 266–274. [PubMed] [Google Scholar]
- May M, Junghaenel DU, Ono M, Stone AA, & Schneider S (2018). Ecological momentary assessment methodology in chronic pain research: A systematic review. The Journal of Pain, 19(7), 699–716. [PMC free article] [PubMed] [Google Scholar]
- National Academies of Sciences, Engineering, and Medicine. (2017). In The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington, DC: The National Academies Press. [Google Scholar]
- R Development Core Team (2019). R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing. [Google Scholar]
- Salaffi F, Stancati A, Silvestri CA, Ciapetti A, & Grassi W (2004). Minimal clinically important changes in chronic musculoskeletal pain intensity measured on a numerical rating scale. European Journal of Pain (London, England), 8(4), 283–291. [PubMed] [Google Scholar]
- Salas-Wright CP, Vaughn MG, Cummings-Vaughn LA, Holzer KJ, Nelson EJ, AbiNader M, & Oh S (2017). Trends and correlates of marijuana use among late middle-aged and older adults in the United States, 2002–2014. Drug and Alcohol Dependence, 171, 97–106. [PMC free article] [PubMed] [Google Scholar]
- SAS Institute, Cary, NC. (2013). The SAS system for Windows. Release 9.4 SAS Institute, Cary, NC. [Google Scholar]
- Segura LE, Mauro CM, Levy NS, Khauli N, Philbin MM, Mauro PM, & Martins SS (2019). Association of US medical marijuana laws with nonmedical prescription opioid use and prescription opioid use disorder. JAMA Network Open, 2(7), e197216. [PMC free article] [PubMed] [Google Scholar]
- Shah A, Hayes CJ, Lakkad M, & Martin BC (2019). Impact of medical marijuana legalization on opioid use, chronic opioid use, and high-risk opioid use. J General Internal Medicine, 34(8), 1419–1426. [PMC free article] [PubMed] [Google Scholar]
- Shiffman S, Stone AA, & Hufford MR (2008). Ecological momentary assessment. Annual Review of Clinical Psychology, 4, 1–32. [PubMed] [Google Scholar]
- Spitzer RL, Kroenke K, Williams JB, & Lowe B (2006). A brief measure for assessing generalized anxiety disorder: the GAD-7. Archives of Internal Medicine, 166(10), 1092–1097. [PubMed] [Google Scholar]
- Stockings E, Campbell G, Hall WD, Nielsen S, Zagic D, Rahman R, Murnion B, Farrell M, Weier M, & Degenhardt L (2018). Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies. Pain, 159(10), 1932–1954. [PubMed] [Google Scholar]
- Tomás JM, Galiana L, & Fernández I (2018). The SF-8 Spanish Version for Health-Related Quality of Life assessment: Psychometric study with IRT and CFA models. The Spanish Journal of Psychology, 21, E1. [PubMed] [Google Scholar]
- Turk DC, Dworkin RH, Allen RR, Bellamy N, Brandenburg N, Carr DB, Cleeland C, Dionne R, Farrar JT, Galer BS, Hewitt DJ, Jadad AR, Katz NP, Kramer LD, Manning DC, McCormick CG, McDermott MP, McGrath P, Quessy S, Rappaport BA, Robinson JP, Royal MA, Simon L, Stauffer JW, Stein W, Tollett J, & Witter J (2003). Core outcome domains for chronic pain clinical trials: IMMPACT recommendations. Pain, 106(3), 337–345. [PubMed] [Google Scholar]
- Volkow ND, Baler RD, Compton WM, & Weiss SRB (2014). Adverse health effects of marijuana use. New England Journal of Medicine, 370(23), 2219–2227. [PMC free article] [PubMed] [Google Scholar]
- Volkow ND, & Weiss SRB (2020). Importance of a standard unit dose for cannabis research. Addiction (Abingdon, England), 115(7), 1219–1221. [PMC free article] [PubMed] [Google Scholar]
- Vyas MB, LeBaron VT, & Gilson AM (2018). The use of cannabis in response to the opioid crisis: A review of the literature. Nursing Outlook, 66(1), 56–65. [PubMed] [Google Scholar]
- Ware J, Kosinski M, Dewey J, & Gandek B (2001). How to Score and Interpret Single-Item Health Status Measures: A Manual for Users of the SF-8 Health Survey. Quality Metric Incorporated. [Google Scholar]
- Wen H, & Hockenberry JM (2018). Association of Medical and Adult-Use Marijuana Laws With Opioid Prescribing for Medicaid Enrollees. JAMA Internal Medicine, 178(5), 673–679. [PMC free article] [PubMed] [Google Scholar]
- Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, Keurentjes JC, Lang S, Misso K, Ryder S, Schmidlkofer S, Westwood M, & Kleijnen J (2015). Cannabinoids for medical use: A systematic review and meta-analysis. JAMA, 313(24), 2456–2473. [PubMed] [Google Scholar]
- Wilson KG, Eriksson MY, D’Eon JL, Mikail SF, & Emery PC (2002). Major depression and insomnia in chronic pain. The Clinical Journal of Pain, 18(2), 77–83. [PubMed] [Google Scholar]
Gerelateerde artikelen
- Legalisatie van medische marihuana gunstig voor kankerpatiënten. Minder morfine nodig en minder aan pijn gerelateerde ziekenhuisopnames
- Medicinale cannabis verlicht langdurig pijn bij patienten met chronische pijn, blijkt uit kleine Harvard studie.
- UMCG Groningen gaat onderzoek doen naar effecten van wietolie - cannabis na twee genezen leverkankerpatienten
- Nieuwe overzichtsstudie van de rol die cannabis, marihuana kan spelen in de zorg voor kankerpatienten geeft uitstekend overzicht van stand van zaken
- Medicinale wiet (cannabis - marihuana) vermindert pijnklachten en laat Amerikaanse werknemers ouder dan 50 jaar langer werken na legalisering van de cannabis, blijkt uit 10-jarig onderzoek
- Cannabis gebruik met hoge THC gehaltes leidt tot meer psychoses op latere leeftijd aldus nieuw wetenschappelijk onderzoek
- Recreatief gebruik van marihuana - cannabis sativa verbetert kwaliteit van leven ( depressie, pijn, angst, eetlust) bij nieuw gediagnosteerden van mond- en keelkanker
- 80 procent van amerikaanse oncologen bespreken medische marihuana met hun patienten maar de meesten doen dat zonder voldoende kennis over de effecten en bijwerkingen van medische cannabis
- DE WATERKOKER VAN MIJN TANTE Een verhaal over medicinale cannabis
- Waar kan ik marihuana of cannabis kopen?
- Cannabisstofjes CBD en THC verdienen meer aandacht als toepassing in een behandeling van kanker blijkt uit review studie
- Cannabis olie - wietolie moet wel zorgvuldig geproduceerd en verwarmd worden anders kan het juist schadelijk zijn en kankergroei stimuleren, blijkt uit Nederlandse studie
- Cannabis - marihuana toegevoegd aan opiaten zoals morfine en oxycodon verhoogt pijnstillende effect bij patiënten met chronische pijn en zij hebben daardoor minder morfine c.q. oxycodon nodig
- Cannabis - THC CBD extract geeft 30 procent meer verlichting van pijn bij patiënten met vergevorderde kanker als de pijn niet meer alleen met opiaten als morfine is op te lossen.
- Marihuana - Cannabis verzacht zenuwpijnen (neuropathische pijn) en verbetert slaap en vermindert angstige en depressieve gevoelens blijkt uit een gerandomiseerde kleinschalige studie
- Cannabis - marihuana stimuleert eetlust en verbetert smaak voor kankerpatienten.
- Marihuana - cannabis als medicijn en als pijnstiller en wellicht als medicijn bij Alzheimer - dementie
Plaats een reactie ...
Reageer op "Medicinale cannabis verlicht langdurig pijn bij patienten met chronische pijn, blijkt uit kleine Harvard studie."